During the last session, AIM ImmunoTech Inc (AMEX:AIM)’s traded shares were 1.38 million, with the beta value of the company hitting 0.38. At the end of the trading day, the stock’s price was $0.14, reflecting an intraday loss of -6.98% or -$0.01. The 52-week high for the AIM share is $0.62, that puts it down -342.86 from that peak though still a striking 7.14% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $9.53M, and the average trade volume was 973.14K shares over the past three months.
AIM ImmunoTech Inc (AIM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AIM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
AIM ImmunoTech Inc (AMEX:AIM) trade information
AIM ImmunoTech Inc (AIM) registered a -6.98% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.98% in intraday trading to $0.14, hitting a weekly high. The stock’s 5-day price performance is -9.77%, and it has moved by -27.77% in 30 days. Based on these gigs, the overall price performance for the year is -67.41%.
AIM ImmunoTech Inc (AIM) estimates and forecasts
In the rating firms’ projections, revenue will decrease -0.99% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 100k as predicted by 1 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 65k and 40k respectively. In this case, analysts expect current quarter sales to grow by 53.85% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 42.86%. While earnings are projected to return 50.00% in 2025.
AIM Dividends
AIM ImmunoTech Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 1.99 million shares, is of VANGUARD GROUP INC’s that is approximately 4.021% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.74 million.